ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.The Lancet. Oncology · 2024Trial
- Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis.Frontiers in pediatrics · 2026Article
- Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia.Cells · 2025Review
- EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.Cell communication and signaling : CCS · 2024Article
- Adamantaniline Derivatives Target ATP5B to Inhibit Translation of Hypoxia Inducible Factor-1α.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia.International journal of molecular sciences · 2022Review
- An oncogenic enhancer encodes selective selenium dependency in AML.Cell stem cell · 2022Article
- Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?Best practice & research. Clinical haematology · 2021Review
- Nuclear NADScience advances · 2021Article
- Emerging Immunotherapy for Acute Myeloid Leukemia.International journal of molecular sciences · 2021Review
- Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing.Frontiers in immunology · 2021Article
- High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations.Frontiers in oncology · 2021Article
- Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.Frontiers in immunology · 2020Review
- AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia.Blood · 2019Article
- Review
- Review
- BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.The Journal of clinical investigation · 2019Article
- Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.Frontiers in oncology · 2019Review
- Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.International journal of oncology · 2018Article
- Targeting Leukemia Stem Cells in the Bone Marrow Niche.Biomedicines · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Lina HanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey L JorgensenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chris BrooksStemline Therapeutics, Inc., New York, New York.
Ce ShiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Qi ZhangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Graciela M Nogueras GonzálezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Antonio CavazosDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rongqing PanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hong MuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sa A WangDepartment of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Jin ZhouDepartment of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Gheath Ai-AtrashDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Stefan O CiureaDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mike RettigBone Marrow Transplantation and Leukemia Program, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
John F DiPersioBone Marrow Transplantation and Leukemia Program, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Jorge CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. mkonople@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USHarbin Medical University · CNWashington University in St. Louis · USIo Therapeutics (United States) · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7MBM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3MRETARGETING AGENTS TO TREAT AMLR01CA194552 · NCI · WASHINGTON UNIVERSITY · PI DIPERSIO, JOHN F. · 2015 to 2017
$1.1MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA194552NCI NIH HHS R50 CA211466
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsApoptosisCell Line, TumorCell ProliferationFlow CytometryHumansImmunoconjugatesInterleukin-3 Receptor alpha SubunitLeukemia, Myeloid, AcuteMiceNeoplastic Stem CellsSignal TransductionSingle-Chain AntibodiesXenograft Model Antitumor AssaysImmunoconjugatesInterleukin-3 Receptor alpha SubunitSingle-Chain Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.